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ABSTRACT
Objectives: The objective of this case study is to evaluate the importance of detection, assessment, and reporting of an adverse drug reaction and to 
improve the medication perseverance.
Methods: This is an observational type of case report which was observed and analyzed in Silchar Medical College and Hospital on regular ward 
rounds.
Results: A case report of toxic epidermal necrolysis due to carbamazepine (CBZ) administration by a 47-year-old male patient who presented as a 
follow-up case of ischemic stroke. Causality assessment of the event done with Naranjo’ causality assessment scale suggests to be “Probable.”
Conclusion: Daily, CBZ is being increasingly prescribed for control of pain in neuralgias and diabetic neuropathy, apart from control of seizures. 
Awareness about the drugs implicated in life-threatening drug reactions will help physicians in preventing them by cautious use of the drugs. 
Moreover, proper counseling to the patient regarding the use of medications is of utmost importance, in such life-threatening conditions where 
treatment guidelines remain indistinct.
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INTRODUCTION
Toxic epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS) 
affecting approximately 1 or 2/1,000,000 annually, and are considered 
medical emergencies as they are potentially fatal conditions. Drugs 
are assumed or identified as the main cause of SJS/TEN in most cases, 
but Mycoplasma pneumoniae and herpes simplex virus infections are 
also well-documented causes alongside (mostly rare cases) in which 
the etiology remains unknown [1]. This disease affects the skin and 
mucous membranes at the skin, mouth, eyes, and genitals. It is severe 
and highly weakening adverse drug reactions (ADR) [2]. SJS disorder is 
more likely to occur in people with highly active anti-retroviral therapy 
regimens [3].
TEN and SJS are two forms of the same life-threatening skin disease 
induced by an immune complex mediated hypersensitivity reaction. 
In SJS, a patient has blistering of mucous membranes, typically in the 
mouth, eyes, and genitalia and widespread small blisters that arise 
as erythematous or purpuric maculae. There is a similar blistering of 
mucous membranes, but in addition, the entire top layer of the skin (the 
epidermis) peels off in sheets forming larger areas in the body of TEN 
patients [4].
TEN and SJS are rare but critically ill, severe cutaneous ADR. The 
mortality rates are about 10% in SJS, 10-30% in overlapping SJS/TEN, 
and 30% in TEN [5].
TEN and SJS are classified into type IVc hypersensitivity reactions 
according to a modified Gell and Coombs classification by Adam 
et al. [6] The main effector cells are CD8+ cytotoxic T lymphocytes, 
CD4+ T cells, natural killer cells, and natural killer T cells. Massive 
release of granulysin, perforin, and granzyme B is involved in the 
pathogenesis [7].
Patients develop an acute exanthemous lesions, which progresses 
toward a widespread blistering (TEN) or more limited purpura, 
vesicles (SJS) and erosion of the skin and mucous membranes, resulting 
from apoptosis of keratinocytes. The incidence of SJS is estimated 
to be 1-6 cases per million person-years and of TEN at 0.4-1.2 cases 
per million person-years. Various drugs are reported to be associated 
with a high risk for SJS and TEN. These include several antiepileptic 
agents, especially carbamazepine (CBZ), phenytoin, phenobarbital 
and lamotrigine, antibacterials, anti-inflammatory drugs of the oxicam 
family and allopurinol [8,9].
The Pharmacovigilance Working Team recommended key elements 
of warnings for the product information of CBZ, lamotrigine, 
phenobarbital, phenytoin, meloxicam, piroxicam, tenoxicam, regarding 
their rare risk of life- threatening SJS for the early detection of these 
adverse reactions and subsequent permanent discontinuation of the 
medicine to improve their outcomes [10]. Certain human leukocyte 
antigen (HLA) types are sometimes associated with increased risk of 
SJS, including HLA B1502 [11].
However, recent publications and postmarketing data suggest that 
CBZ associated SJS/TEN occurs at a much higher rate in some Asian 
populations, about 2.5 cases per 1,000 new exposures. The early 
symptoms of fever, malaise, cough, stinging eyes and a sore throat are 
often confused with an upper respiratory tract infection. This rapidly 
progresses to erythematous macules and targeted lesions, epidermal 
detachment, and mucositis. Early painful erythema and blisters of the 
palms and soles are a hallmark of SJS. Drugs such as anti-epileptics 
mainly phenytoin and CBZ were responsible for the majority (44%) of 
the ADR [12].
CBZ is one among the routinely administered medication for the 
treatment of simple and complex partial seizures, neuralgia and alcohol 
withdrawal syndrome. The drug has anticonvulsive and anticholinergic 
properties by reducing excessive nerve signals within the brain and 
restoring the conventional balance of nerve activity. Side effects include 
conditions such as ataxia, vertigo, drowsiness, confusion, headache, 
maculopapular rash, erythema multiforme, SJS, TEN, xerostomia 
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(gastrointestinal), and aplastic anemia [13,14]. We are reporting such 
an interesting case of CBZ induced TEN at a tertiary care hospital in 
the southern part of Assam. The details of this case are discussed and 
analyzed henceforth.
CASE DESCRIPTION
The patient is a 47-year-old male, a follow-up case of Ischemic stroke 
who was diagnosed as Rt/middle cerebral artery (MCA) Territory 
infarction with (Lt) sided Hemiparesis on Jan 2015. He was treated 
conservatively and was on Tab. Ecosprin AV-75 (clopidogrel - 300 mg 
and aspirin - 75 mg) one tab once daily after dinner and was advised to 
continue the same till next follow-up. After about 5 months he visited a 
neurologist with the residual weakness of the left side of the body. He 
was prescribed Tab. CBZ (Zeptol CR) 200 mg and was advised to take a 
half tablet once daily after dinner for 10 days and then one tablet once 
daily after dinner for next 10 days. After taking the drug CBZ for 11 days 
(i.e., half tab once daily for 10 days and one tab once daily for just 
another 1 day) a total of 11 doses, he developed widespread, pruritic, 
erythematous, papular lesions, and blackish scaly skin all over the body. 
It was associated with fever and headache. An excess peeling of skin 
along with intense inflammation of eyes, lips, nose, genitalia, and oral 
cavity also occurred. On physical examination, the patient presented 
with a temperature of 39°C and a blood pressure of 100/70 mmHg. 
On examination, there were ulcerated lesions on the oral mucosa. 
Extensive erythematous plaques were present over the rest of the body 
(more than 30% of the body surface). The patient was subsequently 
admitted in the Department of Dermatology at Silchar Medical College 
and Hospital with a diagnosis of TEN probably due to CBZ. He had no 
personal or family history of skin diseases, neither was he an allergic to 
any known allergens, food or drugs.
Causality assessment of the event was done with Naranjo’ causality 
assessment scale (total score - 7) suggests a causal relationship 
between the drug and reaction is “Probable.”
Physical examination revealed hypotension (B.P-100/64 mm of 
Hg), tachycardia (pulse rate 110 beats/minutes), and tachypnea 
(respiratory rate 52/minutes). The patient was febrile. Clinical 
examination of the skin revealed a generalized peeling of the skin 
with crusting almost all over the body including scalp and genitalia 
(Figs. 1-3). The Nikolsky sign was positive. The erythematous rash 
was present almost all over the body with an epidermal detachment 
of 70% of the body surface area. Loss of eyelashes, congestion of 
conjunctiva with mucopurulent discharge and exposure keratitis 
were also present. Liver and spleen were not palpable. There was no 
associated lymphadenopathy. Liver function tests showed elevated 
aspartate aminotransferase 175 (normal 10-45) U/L and elevated 
alanine aminotransferase 94 (normal 6-48) U/L. His total white 
blood cell count was 4.25×109/L (normal 4-10×109/L). No atypical 
lymphocytosis or eosinophilia was noted. Platelet count was normal. 
Hemoglobin was low (10.2 g/dl). Serum creatinine was 1.4 g/dL. 
The patient had hyponatremia (Na+ 115 mmol/L) and hyperkalemia 
(K+ 7.2 mmol/L), which was corrected appropriately.
The clinical impression was TEN induced by CBZ. The suspected 
medication was stopped immediately. He was given high dose 
intravenous (iv) dexamethasone (dexona) and pheniramine maleate 
(avil) intramuscular injection twice daily, iv ondansetron (emigo) SOS, 
IVF-DNS-RL iv slowly to maintain the fluid and electrolytic balance 
the fluid topical application of clonate (clobetasone) lotion twice 
daily, clinical lotion thrice daily, kenacort (triamcinolone) oral paste 
twice daily, betadine mouthwash once a day was also included in the 
treatment schedule. The patient was made to lie down on the sterile 
banana leaf to prevent sticking of the skin to the bed. Eye lesions were 
treated with topical antibiotic preparations (ciprofloxacin, gentamicin, 
chloramphenicol, and moxifloxacin + dexamethasone) and ocular 
lubricant solution (lacrigel). Eyes were covered with saline-soaked 
sterile pads. The patient was also treated with parenteral antibiotics 
piperacillin+tazobactum combination and linezolid. Supportive 
treatment included parenteral opioids (fentanyl, pentazocine) for pain 
management, iv fluids, and iv albumin. Nutrition was maintained by 
giving protein powder preparation through Ryle’s tube. He was switched 
Fig. 1: Edema and crusting of the lips, nose, and inflammation of 
eyes
Fig. 2: Peeling of skin and erythematous lesions of skin involving 
the back
Fig. 3: Erythematous purpuric macular lesions involving the 
upper limbs, thighs, and genital area
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over to oral betamethasone once the lesions started healing. Tablet 
Betamethasone was slowly tapered and stopped after 4 weeks. Lesions 
healed with post-inflammatory hyperpigmentation approximately by 
the 16th day. After 1 month, the progression of the skin lesions halted, 
and general condition of the patient improved significantly.
The following figures depict the actual condition of the patient with CBZ 
induced TEN.
DISCUSSION
TEN also known as Lyell’s syndrome was first described by Lyell in 1956. 
The word toxic alludes to the constitutional symptoms while necrolysis 
refers to the necrosis and detachment of the full thickness of the 
epidermis [15]. TEN and SJS are related mucocutaneous disorders with 
an estimated incidence of 0.4-1.2 patients per year. Both the diseases are 
associated with higher rates of morbidity and mortality. Overall mortality 
for SJS ranges from 5% to 25%, and that for TEN ranges from 15% to 40%. 
In TEN, maximal skin involvement with a rash is reached within 4 days, 
and sometimes within hours, whereas the corresponding time for SJS is 
1-14 days. About 90% of patients with TEN develop painful erosions in 
their mucosal membranes, approximately 85% have conjunctival lesions, 
and about 35% of those who survive experience ocular sequelae [9].
In this case, the patient was admitted to the hospital with severe rashes, 
peeling of skin as scales all over the body. On physical examination, 
the patient was dehydrated and poorly nourished. This excess peeled 
skin was mainly observed on neck, chest, abdomen, lower back, 
thighs, genitalia, and over the head. The patient dehydrated state was 
attributed to the detachment of epidermal cells and their secretions. 
Drugs are the most common cause accounting for about 65-80% of 
the cases. An immune mechanism is implicated in the pathogenesis, 
but its nature is still unclear. It is primarily directed at drug modified 
epidermal cells [16]. In this report, the patient was a follow-up case of 
Ischemic stroke R/MCA Territory with (L) Hemiparesis diagnosed on 
January 2015. He came for treatment for his LT sided residual weakness 
on May 2015. On the 11th day of his follow-up treatment, the patient 
had his 11th dose on the evening after dinner at around 9 PM. Within 
a span of 4-5 hrs, he developed severe rashes and blisters all over the 
body, the patient visited his doctor next morning, who advised him 
to stop the suspected medication and attend the Dermatology OPD at 
Silchar Medical College and Hospital. Accordingly, the patient rushed 
to the dermatology OPD of Silchar Medical College and Hospital, 
where the physician, on taking a detailed history and through physical 
examination, suspected it to be a case of TEN, probably due to CBZ 
administration. The patient was admitted immediately and initiated 
supportive therapy without further delay.
The following diagnostic criteria must be fulfilled for a case to be 
labeled as TEN.
1. Bullae or erosions involving more than 20% of body surface area or 
three different anatomical sites.
2. Skin peeling in sheets of more than 3 cm.
3. Involvement of non-exposed skin.
4. Mucous membranes involvement.
5. Skin tenderness within 48 hrs of rash.
6.	 Biopsy	confirmation	within	48	hrs.
7. Fever.
8. Bullae arising on an erythematous background.
9. Exclusion of Staphylococcal scalded skin syndrome.
Investigations usually show leukocytosis, albuminuria, water, and 
electrolyte imbalance and raised transaminases [17].
Although the pathogenesis of these lesions is unknown, a number of 
hypothesis has been put forward [18]. Treatment consisted of supportive 
measures such as removal of precipitating agents, good nursing care, 
laying down the patient on a ripple bed, care of the eyes and mouth to 
prevent scarring and infections, along with maintenance of fluid, and 
electrolyte balance. iv fluids were given for 3 days consecutively. iv fluids 
were supplemented with ORS. The patient was prescribed antibiotics iv 
for 3 days and switched over to oral formulations to prevent further 
infections. The patient was put on a high-protein diet. After several days 
of treatment, the patient showed signs of improvement and his overall 
general health conditions also improved.
CONCLUSION
TEN is considered as a life-threatening complication and a medical 
emergency. Its association with the use of CBZ may have a familial 
tendency. Moreover, proper counseling regarding the use of medications 
is of utmost importance, in such life-threatening conditions where 
treatment guidelines remain unclear. It is also advisable to give 
information about adverse drug reaction to the patients who suffered 
from such serious reactions in the past and reporting the same to the 
concerned authority.
Daily, CBZ is being increasingly prescribed for control of pain in 
neuralgias and diabetic neuropathy apart from using it as an anti-
seizures agent. Awareness about the drugs implicated in life-threatening 
drug reactions will help physicians as well other health-care providers 
in early detection and prevention of ADRs by cautious use of such drugs.
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